Terumo (4543) investor relations material

Financial performance and guidance

• Achieved record-high revenue and profit in FY25, with a 5-year company-wide revenue CAGR of 12%.

• FY26 guidance targets 9% YoY revenue growth (8% excluding FX) and 20% operating profit margin, excluding new M&A.

• All GS26 financial targets are expected to be achieved, with steady operational improvements enhancing profitability.

• Two M&As executed in FY25 accelerated business expansion and growth.

Cardiac and vascular (C&V) business strategy

• C&V segment expects high single-digit revenue growth and a 2.5pt AOP improvement in FY26.

• Growth driven by stable access business, new therapeutic product launches, and production transfer initiatives.

• Launch of innovative DSS imaging system and Kanshas drug-coated balloon to strengthen category leadership.

• Expansion of transradial access (TRA) across disease areas, aiming for significant adoption increases by 2026.

Medical care solutions (TMCS) and CDMO expansion

• TMCS targets 8% YoY revenue growth and 29% AOP increase (margin 14%) in FY26, excluding FX and recent plant acquisition.

• Growth drivers include global CDMO business expansion, new project launches, and PLAJEX capacity increases.

• Acquisition of Leverkusen plant in Germany establishes first overseas CDMO site, with PLAJEX production line operational by 2027.

• CDMO business leverages integrated device and pharmaceutical expertise, aiming for 100 billion yen in revenue.